Library resources - Almac

Client login

Search

Home / Knowledge Centre /

Clinical Technologies

Search

Topic

What is IRT and How Does it Impact Clinical Trials?

What is Interactive Response Technology (IRT) or Randomization and Trial Supply Management System (RTSM)? An IRT system is known by…

Visit Management Factsheet

Technical Sheet

Visit Management Factsheet

Technical Sheet

eCOA Factsheet

Fact Sheet: Live Study Data Review – IRT Data Monitoring Services

Technical Sheet

Fact Sheet: Live Study Data Review – IRT Data Monitoring Services

Overcoming IRT challenges for small and emerging biotech: The benefits of IXRS®3

Overcoming IRT challenges for small and emerging biotech: The benefits of IXRS®3

Make an Enquiry

If you are interested in our Clinical Technologies, then please contact us

Contact Us

Clinical Technologies: Expert Insights and Predictions for 2025

Managing three mega-trials with unique supply constraints: Creative approaches using IXRS®3 to mitigate risk of inventory disruptions

IRT implementation considerations for Bayesian response-adaptive randomization in platform trials

Ensuring efficient adaptions for platform trials: Planning for successful program management

The Argument for Data Alignment and Integration in Clinical Supply Management

Unique IRT Implementation Considerations for Personalised Medicine Trials

Technical Sheet

Almac Clinical Technologies Biostatistics Group

Master Protocols: Implementing effective treatment adaptations in the randomisation

Interactive Response Technology User Support: Where eClinical Software and a Site-Centric Mindset Converge

Leveraging IRT User Acceptance Testing Strategy to Navigate Clinical Trial Complexity

Streamlining Clinical Trial Supply Management and Reporting with Drug Pooling in the IRT World

Technical Sheet

IXRS®3 Decentralised Trials Support

Technical Sheet

IXRS®3 Drug Pooling: Multi-protocol supply management

Technical Sheet

ART™ (Accountability & Reconciliation Tracking)

Rapid Onboarding for Master Protocols

Managing regulated IP in Japan

A two-month lockdown in Shanghai

Supporting small domestic trials cost effectively

Care is Critical- Lessons Learned from Clinical Trial Inspections

How DCT Technology Partnerships a Better Patient Journey, Diversity, and Adherence

Is Your IRT Ready to Support Direct-to-Patient Shipments?

Innovative Electronic Patient Identification System

Flexible IXRS® design supports multiple extension studies

Ensuring study integrity and reliability during a drug recall

Boehringer Ingelheim relies on Almac Clinical Technologies for EDC/IRT integration

Accommodating Last-Minute Design Changes

Meeting regulatory requirements in Japan: Customised IXRS® manages patient-specific drug orders

Weighing the options in addressing a supply issue

Total supply chain assurance program turns around global trial

Temperature Surveillance

Supporting a regulatory submission proactively

Supplying costly investigational product: Pre-randomisation approach reduces drug wastage

Smooth operations after a cyberattack: Quick thinking and extra coordination preserves drug supply and patient safety

Seamless adoption of mid-study protocol change

Preparing “Plan B” for a mega study in the event of a supply issue

Managing drug and dose assignments

Managing 24 protocol amendments across a complex development program

Maintaining compliance with new ICH monitoring guidelines

Clinical Trials Need Preventative Maintenance Just Like Cars Do, and Here is Why

5 Points of Operational Readiness

Automated Accountability and Reconciliation

Supporting the race for a COVID-19 therapy

State of the Industry Report: Embracing Trial Change and Elevating IRT Systems

The secrets of a successful supply strategy

IRT system customisations – necessary or nice to have?

Catching up during COVID: Proven technology for meeting accelerated timelines

Accelerating Outcomes with a Pancreatic Cancer Adaptive Platform

Adaptations and Solutions for Clinical Supply Chain Challenges

So, you want to run a decentralised clinical trial…

How to Add a New Randomized Part to an Ongoing Study in Three Weeks

Accommodating a Flexible Visit Schedule

A Competitive Race: Accelerating the Development Timeline With A Multi-Trial IRT Programme

ART™ – Automated Accountability: Maintaining a chain of custody from release to destruction

Small Biotech Company Running a Phase II Study with Limited Drug Availability

A New Resupply Strategy Turns an Emergency into an Opportunity

From FDA Approval to Product Launch

Meet the Experts

Learn more about our experts in your discipline today

Find out More

Stay up-to-date with the latest from Almac

Join our mailing list

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies